Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma

StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment target: 37 to 40
    • Primary and study completion dates: Jun 1, 2026 to Nov 1, 2026
    • Eligibility criteria expanded, about 252 words
    v6
  2. Secondary endpoints: details revised at 4 of 4 entriesv5
  3. Re-verified, no change to tracked fieldsv4
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 1, 2021 to Dec 20, 2021
    • Site details revised
    v3
  5. Primary and study completion dates: Mar 1, 2025 to Jun 1, 2026
    • Start date: Sep 1, 2020 to Jun 1, 2021
    v2
  6. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase 2 open-label study to test the safety and effectiveness of combining pembrolizumab and bendamustine in patients with relapsed (cancer that has come back or started getting worse) or refractory (cancer that is not responding or has stopped responding to treatment) Hodgkin lymphoma.
Trial Details
NCT Number NCT04510636
Lead Sponsor University Health Network, Toronto
Conditions
(from sponsor)		 Classical Hodgkin Lymphoma, Relapsed Cancer, Refractory Cancer
Related terms Neoplasms, Recurrence
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov